481 related articles for article (PubMed ID: 10582699)
21. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
22. Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc.
Herr AB; Ballister ER; Bjorkman PJ
Nature; 2003 Jun; 423(6940):614-20. PubMed ID: 12768205
[TBL] [Abstract][Full Text] [Related]
23. Recombinant human monoclonal igA antibody against CEA to recruit neutrophils to CEA-expressing cells.
Zhao J; Kuroki M; Shibaguchi H; Wang L; Huo Q; Takami N; Tanaka T; Kinugasa T; Kuroki M
Oncol Res; 2008; 17(5):217-22. PubMed ID: 18980018
[TBL] [Abstract][Full Text] [Related]
24. Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma.
Elsässer D; Stadick H; Stark S; Van de Winkel JG; Gramatzki M; Schrott KM; Valerius T; Schafhauser W
Anticancer Res; 1999; 19(2C):1525-8. PubMed ID: 10365137
[TBL] [Abstract][Full Text] [Related]
25. Anti-inflammatory activity of human IgA antibodies and their Fab alpha fragments: inhibition of IgG-mediated complement activation.
Russell MW; Reinholdt J; Kilian M
Eur J Immunol; 1989 Dec; 19(12):2243-9. PubMed ID: 2606139
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment.
Naundorf S; Preithner S; Mayer P; Lippold S; Wolf A; Hanakam F; Fichtner I; Kufer P; Raum T; Riethmüller G; Baeuerle PA; Dreier T
Int J Cancer; 2002 Jul; 100(1):101-10. PubMed ID: 12115595
[TBL] [Abstract][Full Text] [Related]
27. Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor.
Repp R; Valerius T; Sendler A; Gramatzki M; Iro H; Kalden JR; Platzer E
Blood; 1991 Aug; 78(4):885-9. PubMed ID: 1714327
[TBL] [Abstract][Full Text] [Related]
28. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
[TBL] [Abstract][Full Text] [Related]
29. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
Würflein D; Dechant M; Stockmeyer B; Tutt AL; Hu P; Repp R; Kalden JR; van de Winkel JG; Epstein AL; Valerius T; Glennie M; Gramatzki M
Cancer Res; 1998 Jul; 58(14):3051-8. PubMed ID: 9679970
[TBL] [Abstract][Full Text] [Related]
30. Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody.
Paul S; Bizouarne N; Dott K; Ruet L; Dufour P; Acres RB; Kieny MP
Cancer Gene Ther; 2000 Apr; 7(4):615-23. PubMed ID: 10811480
[TBL] [Abstract][Full Text] [Related]
31. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
[TBL] [Abstract][Full Text] [Related]
32. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.
Preithner S; Elm S; Lippold S; Locher M; Wolf A; da Silva AJ; Baeuerle PA; Prang NS
Mol Immunol; 2006 Mar; 43(8):1183-93. PubMed ID: 16102830
[TBL] [Abstract][Full Text] [Related]
33. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
34. Pneumococcal capsular polysaccharide-specific IgA triggers efficient neutrophil effector functions via FcalphaRI (CD89).
van der Pol W; Vidarsson G; Vilé HA; van de Winkel JG; Rodriguez ME
J Infect Dis; 2000 Oct; 182(4):1139-45. PubMed ID: 10979910
[TBL] [Abstract][Full Text] [Related]
35. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
36. Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies.
Lohse S; Peipp M; Beyer T; Valerius T; Dechant M
Arch Immunol Ther Exp (Warsz); 2010 Aug; 58(4):303-12. PubMed ID: 20508996
[TBL] [Abstract][Full Text] [Related]
37. Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells.
Pascal V; Laffleur B; Debin A; Cuvillier A; van Egmond M; Drocourt D; Imbertie L; Pangault C; Tarte K; Tiraby G; Cogné M
Haematologica; 2012 Nov; 97(11):1686-94. PubMed ID: 22689689
[TBL] [Abstract][Full Text] [Related]
38. Functional in vitro studies of recombinant human immunoglobulin G and immunoglobulin A anti-D.
Nielsen LK; Green TH; Norderhaug L; Sandlie I; Dziegiel MH
Transfusion; 2007 Feb; 47(2):306-15. PubMed ID: 17302778
[TBL] [Abstract][Full Text] [Related]
39. Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide.
Preston MJ; Gerçeker AA; Reff ME; Pier GB
Infect Immun; 1998 Sep; 66(9):4137-42. PubMed ID: 9712759
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]